News Sentiment

VYNE sentiment intelligence

Vyne Therapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 52 Balanced news tone 51 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 0.64 Week of 10 Jul 2026
Weighted tone 52/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

74/100 classification confidence.

Company focus 43

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend active

-6.2% over one week, -1.7% over four weeks, trend active, and below fair value.

Latest direct headline Neutral

VYNE Therapeutics Inc. (VYNE) reports 13.8% stake by Zhang Xiaofan

Market Reaction

Price moving ahead of tone

58/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 74/100 classification
One-week reaction -6.2% Price reacting lower
Trend fit Trend active -1.7% over four weeks
Fair value -65.2% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 7
Neutral 41
Negative 3

Relevance

Why the article matched

Direct first
Direct company coverage 43
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 14
TradingView 8
TradingKey 7
Market source 5
simplywall.st 3
AD HOC NEWS 2
GuruFocus 1
Moomoo 1

Event Lens

What the news is about

Classified themes
Market update 19
Earnings 13
Deals and strategy 10
Capital return 4
Regulatory and legal 2
Balance sheet 2
Guidance 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 51
Stock Titan Direct company coverage

VYNE Therapeutics Inc. (VYNE) reports 13.8% stake by Zhang Xiaofan

Zhang Xiaofan has reported a 13.8% beneficial ownership stake in VYNE Therapeutics Inc., holding 4,595,118 shares of common stock. This SCHEDULE 13G/A filing indicates that Zhang Xiaofan has sole voting and dispositive power over these shares. The filing lists Zhang Xiaofan's bus

Tone
Neutral 50/100
Event
Deals and strategy
Published
14 Jul 2026 13:39
Source
Stock Titan
Stock Titan Direct company coverage

VYNE Therapeutics (NASDAQ: VYNE) shares Yarrow transaction deck

VYNE Therapeutics Inc. (NASDAQ: VYNE) reported that Yarrow Bioscience, Inc. has published an investor presentation for investor relations, dated July 14, 2026. This presentation has been made available on VYNE's investor website and filed as Exhibit 99.1. It is clarified that thi

Tone
Neutral 50/100
Event
Market update
Published
14 Jul 2026 12:39
Source
Stock Titan
Stock Titan Direct company coverage

VYNE Therapeutics (NASDAQ: VYNE) outlines Yarrow merger, dividend terms

VYNE Therapeutics has detailed its proposed reverse merger with Yarrow Bioscience, where the combined company will trade as YARW on Nasdaq around July 24, 2026. Yarrow, founded in 2025, is developing YB-101, an anti-TSHR antibody for Graves’ disease and thyroid eye disease, with

Tone
Neutral 50/100
Event
Deals and strategy
Published
14 Jul 2026 12:39
Source
Stock Titan
Stock Titan Direct company coverage

VYNE Therapeutics (NASDAQ: VYNE) declares $0.38/share special dividend tied to merger

VYNE Therapeutics has declared an estimated $0.38 per share special cash dividend, totaling $16.5 million, in connection with its proposed merger with Yarrow Bioscience. The dividend is payable to shareholders of record as of July 22, 2026, and its payment is conditional upon the

Tone
Positive 60/100
Event
Capital return
Published
11 Jul 2026 11:11
Source
Stock Titan
Moomoo Direct company coverage

VYNE Therapeutics Announces Special Cash Dividend in Connection With Pending Merger With Yarrow Bioscience

VYNE Therapeutics announced a special cash dividend of $1.52 per share of common stock in connection with its pending merger with Yarrow Bioscience. The record date for the dividend is set for August 2, 2026, payable on August 5, 2026, contingent upon the closing of the merger. T

Tone
Positive 65/100
Event
Deals and strategy
Published
11 Jul 2026 09:11
Source
Moomoo
Stock Titan Direct company coverage

$16.5 million special payout for VYNE holders hinges on Yarrow merger vote

VYNE Therapeutics (Nasdaq: VYNE) has declared a special cash dividend of an estimated $16.5 million, or approximately $0.38 per share, contingent on its proposed merger with Yarrow Bioscience. The payout is set for stockholders and warrant holders of record as of July 22, 2026, w

Tone
Negative 40/100
Event
Deals and strategy
Published
10 Jul 2026 23:39
Source
Stock Titan
TradingView Direct company coverage

VYNE Therapeutics declares $16.5M special cash dividend tied to Yarrow merger

VYNE Therapeutics announced a special cash dividend of $16.5 million, approximately $0.38 per share, in anticipation of its merger with Yarrow Bioscience. The dividend is payable to stockholders and warrant holders of record as of July 22, 2026, with payment on July 23, 2026. Thi

Tone
Positive 67/100
Event
Deals and strategy
Published
10 Jul 2026 12:40
Source
TradingView
Benzinga Direct company coverage

12 Health Care Stocks Moving In Friday's Pre-Market Session

This article identifies 12 healthcare stocks that experienced significant movement in Friday's pre-market session. It lists both gainers, such as VYNE Therapeutics and WORK Medical Tech Gr, and losers, including SILO Pharma and Virax Biolabs Group, detailing their percentage chan

Tone
Positive 73/100
Event
Market update
Published
10 Jul 2026 11:40
Source
Benzinga
AD HOC NEWS Direct company coverage

VYNE stock holds its ground. Focus turns to the company profile.

This article focuses on VYNE Therapeutics Inc. (VYNE), a clinical-stage biopharmaceutical company specializing in dermatology programs. The company's profile is defined by its pipeline development and capital allocation strategies, which are crucial for investor sentiment. Tradin

Tone
Neutral 50/100
Event
Regulatory and legal
Published
07 Jul 2026 11:11
Source
AD HOC NEWS
Finviz Direct company coverage

VYNE - VYNE Therapeutics Inc Forecast, Target Price

This article provides a detailed financial overview and forecast for VYNE Therapeutics Inc (VYNE). It includes key metrics such as market capitalization, income, sales, P/E ratios, insider and institutional ownership, profitability, and stock performance data. The company's targe

Tone
Neutral 50/100
Event
Guidance
Published
06 Jul 2026 09:40
Source
Finviz
Investing.com Nigeria Direct company coverage

Form 4 Vyne Therapeutics Inc For: 2 July By Investing.com

This article announces the filing of Form 4 for Vyne Therapeutics Inc. on July 2nd. It provides key financial market data including indices, commodities, bonds, and shares, noting performance metrics and top movers. The content also features popular articles and investment challe

Tone
Neutral 50/100
Event
Market update
Published
03 Jul 2026 21:11
Source
Investing.com Nigeria
Stock Titan Direct company coverage

VYNE Therapeutics (VYNE) CSO reports 2,370-share tax withholding on RSU vesting

Stuart Iain, the Chief Scientific Officer of VYNE Therapeutics (VYNE), had 2,370 shares of common stock withheld by the company. This action was taken to cover tax obligations related to the vesting of restricted stock units, with each share valued at $0.6507. Following this non-

Tone
Neutral 50/100
Event
Market update
Published
03 Jul 2026 00:10
Source
Stock Titan
Stock Titan Direct company coverage

VYNE (VYNE) CFO reports 3,464-share tax withholding on RSU vesting

VYNE Therapeutics Inc. CFO Tyler Zeronda reported a routine tax-related share disposition. On June 30, 2026, 3,464 shares of common stock were withheld to cover tax obligations from the vesting of restricted stock units. After this transaction, Zeronda directly held 97,434 shares

Tone
Neutral 50/100
Event
Market update
Published
03 Jul 2026 00:10
Source
Stock Titan
Stock Titan Direct company coverage

VYNE (VYNE) CEO Domzalski has 12,214 shares withheld for RSU taxes

VYNE Therapeutics Inc.'s President and CEO, David Domzalski, had 12,214 common shares withheld by the company to satisfy tax obligations related to the vesting of restricted stock units. This transaction, categorized as a tax-related disposition (transaction code F), occurred at

Tone
Neutral 50/100
Event
Market update
Published
03 Jul 2026 00:10
Source
Stock Titan
TradingView Direct company coverage

Price to sales forward of VYNE Therapeutics Inc. – NASDAQ:VYNE

This article provides a brief snapshot of the "Price to sales forward" metric for VYNE Therapeutics Inc. (NASDAQ: VYNE) as listed on TradingView. It indicates the stock market where VYNE is traded and notes that the market was closed at the time of data retrieval with no trades.

Tone
Neutral 50/100
Event
Market update
Published
27 Jun 2026 21:09
Source
TradingView
TradingView Direct company coverage

Price to book forward of VYNE Therapeutics Inc. – NASDAQ:VYNE

This article provides a financial metric for VYNE Therapeutics Inc. (NASDAQ: VYNE), specifically its "Price to book forward" value. It indicates that the NASDAQ market was closed at the time of publication and there were no trades. The content is primarily a data placeholder from

Tone
Neutral 50/100
Event
Market update
Published
27 Jun 2026 20:10
Source
TradingView
TradingView Direct company coverage

Price to earnings forward of VYNE Therapeutics Inc. – NASDAQ:VYNE

This article provides financial information for VYNE Therapeutics Inc. (NASDAQ: VYNE), specifically focusing on its forward price-to-earnings ratio. It presents a table showing the period, value, change, and percentage change for this metric, noting that the data is generated by

Tone
Neutral 50/100
Event
Earnings
Published
27 Jun 2026 11:40
Source
TradingView
TradingView Direct company coverage

Enterprise value to EBITDA forward of VYNE Therapeutics Inc. – NASDAQ:VYNE

This article provides financial information for VYNE Therapeutics Inc. (NASDAQ: VYNE), focusing on its Enterprise Value to EBITDA (EV/EBITDA) forward metric. The content appears to be a stub or a data point from a financial platform, indicating the metric's value and any changes

Tone
Neutral 50/100
Event
Market update
Published
27 Jun 2026 01:11
Source
TradingView
TradingView Direct company coverage

VYNE Therapeutics Inc Actuals & Estimates (NASDAQ:VYNE)

This article provides financial actuals and estimates for VYNE Therapeutics Inc. (NASDAQ:VYNE), including its current stock price, market capitalization, volatility, and earnings information. It highlights that VYNE has a market cap of $21.76M, a 6.08% stock volatility, and repor

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 07:11
Source
TradingView
TradingView Direct company coverage

VYNE Therapeutics Inc Actuals & Estimates (BOATS:VYNE)

This article provides an overview of VYNE Therapeutics Inc. (BOATS:VYNE) financial actuals and estimates, including its income statement, balance sheet, and cash flow data for both annual and quarterly periods. It also addresses frequently asked questions about the company's stoc

Tone
Neutral 50/100
Event
Balance sheet
Published
25 Jun 2026 18:10
Source
TradingView